Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment

Elias Jabbour, Sameer A Parikh, Hagop Kantarjian, Jorge Cortes

Research output: Contribution to journalReview article

24 Citations (Scopus)

Abstract

Imatinib mesylate has revolutionized the treatment landscape for patients with newly diagnosed chronic myeloid leukemia. Follow-up has shown excellent response rates, progression-free survival, and overall survival after 8 years. However, some patients develop resistance to imatinib treatment because of a multitude of reasons. Strategies to overcome resistance include dose escalation of imatinib or switching to a second-generation tyrosine kinase inhibitor or to one of the newer non-tyrosine kinase inhibitors. This article guides the treating physician with a rational approach in the management of patients with chronic myeloid leukemia who fail initial treatment with imatinib or lose response while on therapy with imatinib.

Original languageEnglish (US)
Pages (from-to)981-995
Number of pages15
JournalHematology/Oncology Clinics of North America
Volume25
Issue number5
DOIs
StatePublished - Oct 2011
Externally publishedYes

Fingerprint

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Therapeutics
Protein-Tyrosine Kinases
Disease-Free Survival
Phosphotransferases
Imatinib Mesylate
Physicians
Survival

Keywords

  • Homoharringtonine
  • Multikinase inhibitors
  • Mutation screening
  • Myeloproliferative disorders
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Chronic Myeloid Leukemia : Mechanisms of Resistance and Treatment. / Jabbour, Elias; Parikh, Sameer A; Kantarjian, Hagop; Cortes, Jorge.

In: Hematology/Oncology Clinics of North America, Vol. 25, No. 5, 10.2011, p. 981-995.

Research output: Contribution to journalReview article

Jabbour, Elias ; Parikh, Sameer A ; Kantarjian, Hagop ; Cortes, Jorge. / Chronic Myeloid Leukemia : Mechanisms of Resistance and Treatment. In: Hematology/Oncology Clinics of North America. 2011 ; Vol. 25, No. 5. pp. 981-995.
@article{d3db0a73f60a46bd80ae659d6d475666,
title = "Chronic Myeloid Leukemia: Mechanisms of Resistance and Treatment",
abstract = "Imatinib mesylate has revolutionized the treatment landscape for patients with newly diagnosed chronic myeloid leukemia. Follow-up has shown excellent response rates, progression-free survival, and overall survival after 8 years. However, some patients develop resistance to imatinib treatment because of a multitude of reasons. Strategies to overcome resistance include dose escalation of imatinib or switching to a second-generation tyrosine kinase inhibitor or to one of the newer non-tyrosine kinase inhibitors. This article guides the treating physician with a rational approach in the management of patients with chronic myeloid leukemia who fail initial treatment with imatinib or lose response while on therapy with imatinib.",
keywords = "Homoharringtonine, Multikinase inhibitors, Mutation screening, Myeloproliferative disorders, Tyrosine kinase inhibitors",
author = "Elias Jabbour and Parikh, {Sameer A} and Hagop Kantarjian and Jorge Cortes",
year = "2011",
month = "10",
doi = "10.1016/j.hoc.2011.09.004",
language = "English (US)",
volume = "25",
pages = "981--995",
journal = "Hematology/Oncology Clinics of North America",
issn = "0889-8588",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Chronic Myeloid Leukemia

T2 - Mechanisms of Resistance and Treatment

AU - Jabbour, Elias

AU - Parikh, Sameer A

AU - Kantarjian, Hagop

AU - Cortes, Jorge

PY - 2011/10

Y1 - 2011/10

N2 - Imatinib mesylate has revolutionized the treatment landscape for patients with newly diagnosed chronic myeloid leukemia. Follow-up has shown excellent response rates, progression-free survival, and overall survival after 8 years. However, some patients develop resistance to imatinib treatment because of a multitude of reasons. Strategies to overcome resistance include dose escalation of imatinib or switching to a second-generation tyrosine kinase inhibitor or to one of the newer non-tyrosine kinase inhibitors. This article guides the treating physician with a rational approach in the management of patients with chronic myeloid leukemia who fail initial treatment with imatinib or lose response while on therapy with imatinib.

AB - Imatinib mesylate has revolutionized the treatment landscape for patients with newly diagnosed chronic myeloid leukemia. Follow-up has shown excellent response rates, progression-free survival, and overall survival after 8 years. However, some patients develop resistance to imatinib treatment because of a multitude of reasons. Strategies to overcome resistance include dose escalation of imatinib or switching to a second-generation tyrosine kinase inhibitor or to one of the newer non-tyrosine kinase inhibitors. This article guides the treating physician with a rational approach in the management of patients with chronic myeloid leukemia who fail initial treatment with imatinib or lose response while on therapy with imatinib.

KW - Homoharringtonine

KW - Multikinase inhibitors

KW - Mutation screening

KW - Myeloproliferative disorders

KW - Tyrosine kinase inhibitors

UR - http://www.scopus.com/inward/record.url?scp=80755159112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80755159112&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2011.09.004

DO - 10.1016/j.hoc.2011.09.004

M3 - Review article

C2 - 22054730

AN - SCOPUS:80755159112

VL - 25

SP - 981

EP - 995

JO - Hematology/Oncology Clinics of North America

JF - Hematology/Oncology Clinics of North America

SN - 0889-8588

IS - 5

ER -